Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation

Table 2 Furosemide trials

Furosemide	Singh [5] prospective RCT 24 hours (1992)	Luciano [6] prospective RCT 24 hours (1997)	Klinge [7] prospective RCT 72 hours (1997)			van der Vorst [8] prospective observational 72 hours (2001)
Intermittent
Patients (n)	12	15	23
Continuous
Patients (n)	8	11	23			12
Intermittent
Age	1.44 (± 1.4) years	3.7 (± 3.4) months	2.4 (± 2.1) years			13 (0–33) weeks^a
Continuous
Age	2.3 (± 2.2) years	1.8 (± 2.5) months	3.4 (± 3.1) years
P value	NS	0.1	NS
Study day			1	2	3	1	2	3
Intermittent dose mg/kg per 24 hours	6.23 (± 0.62)	6.8 (± 1.2)	1.6 (± 0.6)	0.9 (± 0.5)	1.0 (± 0.5)
Continuous dose mg/kg per 24 hours						2.2 (± 0.4)	4.2 (± 1.1)	3.6 (± 1.3)
P value	0.045	0.001	0.014	0.0003	0.014
Intermittent UO (ml/kg per hour)	3.53 (± 4.1)	3.3 (± 1.1)	3.1 (± 0.8)	2.9 (± 1.1)	2.9 (± 1.0)
Continuous UO (ml/kg per hour)	3.36 (± 1.79)	2.5 (± 1.1)	2.7 (± 0.8)	2.9 (± 0.9)	3.6 (± 1.1)	2.4 (0.6–5.2)^a	5.8 (3.5–9.1)^a	5.4 (3.6–7.4)^a
P value	NS	0.05	NS	NS	NS
Intermittent UO/variance	13.07 (± 14.56) ml/kg per hour	3.8 (± 2.1)
Intermittent UO/variance maximal			15.8 (± 3.7) ml/kg per hour
Intermittent UO/variance minimal			0.3 (± 0.2) ml/kg per hour
Continuous UO/variance	2.19 (± 1.92) ml/kg per hour	1.9 (± 1.6)
Continuous UO/variance maximal			9.4 (± 4.1) ml/kg per hour
Continuous UO/variance minimal			0.5 (± 0.3) ml/kg per hour
P value	0.045	0.02	< 0.0001

^aMedian (range). Data given as mean (standard deviation) unless indicated otherwise. NS, not significant; RCT, randomised controlled trial; UO, urine output.

ISSN: 1364-8535